
David Metzger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10753289/publications.pdf Version: 2024-02-01



DAVID METZCER

#	Article	IF	CITATIONS
1	The fifth edition of the addiction severity index. Journal of Substance Abuse Treatment, 1992, 9, 199-213.	1.5	3,878
2	The efficacy of a network intervention to reduce HIV risk behaviors among drug users and risk partners in Chiang Mai, Thailand and Philadelphia, USA. Social Science and Medicine, 2009, 68, 740-748.	1.8	147
3	Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. Aids, 1998, 12, 785-793.	1.0	133
4	Non-injection substance use correlates with risky sex among men having sex with men: data from HIVNET1The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.1. Drug and Alcohol Dependence, 1999, 53, 197-205.	1.6	115
5	Are US Populations Appropriate for Trials of Human Immunodeficiency Virus Vaccine?. American Journal of Epidemiology, 2001, 153, 619-627.	1.6	112
6	Willingness to Volunteer in Future Preventive HIV Vaccine Trials: Issues and Perspectives From Three U.S. Communities. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 63-71.	0.9	109
7	The dynamic relationship between social norms and behaviors: the results of an <scp>HIV</scp> prevention network intervention for injection drug users. Addiction, 2013, 108, 934-943.	1.7	77
8	High-Risk Behaviors for HIV: A Comparison Between Crack-Abusing and Opioid-Abusing African-American Women. Journal of Psychoactive Drugs, 1994, 26, 233-241.	1.0	68
9	Determinants of condom use among intravenous drug users. Aids, 1993, 7, 719-724.	1.0	67
10	Relationships between social norms, social network characteristics, and HIV risk behaviors in Thailand and the United States Health Psychology, 2009, 28, 323-329.	1.3	65
11	Substance Use Among Men Who Have Sex With Men: Comparison With a National Household Survey. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 86-90.	0.9	59
12	New scales to assess change in the Addiction Severity Index for the opioid, cocaine, and alcohol dependent Psychology of Addictive Behaviors, 1998, 12, 233-246.	1.4	54
13	Differences in the rate of nicotine metabolism among smokers with and without HIV. Aids, 2019, 33, 1083-1088.	1.0	36
14	Placebo-controlled randomized clinical trial testing the efficacy and safety of varenicline for smokers with HIV. Drug and Alcohol Dependence, 2019, 200, 26-33.	1.6	34
15	Preliminary Estimates of Human Immunodeficiency Virus Prevalence and Incidence Among Cocaine Abusers of Porto Alegre, Brazil. Journal of Urban Health, 2003, 80, 115-126.	1.8	31
16	Using Interrupted Time Series Analysis to Measure the Impact of Legalized Syringe Exchange on HIV Diagnoses in Baltimore and Philadelphia. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, S148-S154.	0.9	29
17	Willingness to Volunteer in Future Preventive HIV Vaccine Trials: Issues and Perspectives From Three U.S. Communities. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 63-71.	0.9	25
18	Substance Use Among Men Who Have Sex With Men: Comparison With a National Household Survey. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 86-90.	0.9	25

DAVID METZGER

#	Article	IF	CITATIONS
19	Validity of three measures of antisociality in predicting HIV risk behaviors in methadone-maintenance patients. Drug and Alcohol Dependence, 1997, 47, 99-107.	1.6	22
20	The nature and consequences of cognitive deficits among tobacco smokers with HIV: a comparison to to tobacco smokers without HIV. Journal of NeuroVirology, 2017, 23, 550-557.	1.0	22
21	Ethical issues in HIV prevention research with people who inject drugs. Clinical Trials, 2014, 11, 239-245.	0.7	18
22	Methadone maintenance for HIV positive and HIV negative patients in Kyiv: Acceptability and treatment response. Drug and Alcohol Dependence, 2014, 137, 62-67.	1.6	18
23	Sociodemographic and Behavioral Characteristics Associated with Timeliness and Retention in a 6-Month Follow-up Study of High-Risk Injection Drug Users. American Journal of Epidemiology, 2003, 157, 930-939.	1.6	17
24	Assessment of Contamination and Misclassification Biases in a Randomized Controlled Trial of a Social Network Peer Education Intervention to Reduce HIV risk Behaviors Among Drug Users and Risk Partners in Philadelphia, PA and Chiang Mai, Thailand. AIDS and Behavior, 2015, 19, 1818-1827.	1.4	15
25	Evaluating network-level predictors of behavior change among injection networks enrolled in the HPTN 037 randomized controlled trial. Drug and Alcohol Dependence, 2017, 175, 164-170.	1.6	14
26	Client and Provider Perspectives on Antiretroviral Treatment Uptake and Adherence Among People Who Inject Drugs in Indonesia, Ukraine and Vietnam: HPTN 074. AIDS and Behavior, 2019, 23, 1084-1093.	1.4	14
27	Risk behavior among women enrolled in a randomized controlled efficacy trial of an adenoviral vector vaccine to prevent HIV acquisition. Aids, 2013, 27, 1763-1770.	1.0	13
28	Regional differences between people who inject drugs in an <scp>HIV</scp> prevention trial integrating treatment and prevention (<scp>HPTN</scp> 074): a baseline analysis. Journal of the International AIDS Society, 2018, 21, e25195.	1.2	13
29	Brief Report: Rate of Nicotine Metabolism and Tobacco Use Among Persons With HIV: Implications for Treatment and Research. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, e36-e40.	0.9	13
30	Glucocorticoid–immune response to acute stress in women and men living with HIV. Journal of Behavioral Medicine, 2019, 42, 1153-1158.	1.1	13
31	Recruitment of Urban US Women at Risk for HIV Infection and Willingness to Participate in Future HIV Vaccine Trials. AIDS and Behavior, 2013, 17, 760-772.	1.4	12
32	Effect of GB virus C viremia on HIV acquisition and HIV set-point. Aids, 2005, 19, 1910-1912.	1.0	11
33	Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058. International Journal of Drug Policy, 2012, 23, 162-165.	1.6	10
34	Designing an Individually Tailored Multilevel Intervention to Increase Engagement in HIV and Substance Use Treatment Among People Who Inject Drugs With HIV: HPTN 074. AIDS Education and Prevention, 2019, 31, 95-110.	0.6	9
35	Effect of Opioid Use on Immune Activation and HIV Persistence on ART. Journal of NeuroImmune Pharmacology, 2020, 15, 643-657.	2.1	9
36	Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand. Drug and Alcohol Dependence, 2014, 142, 139-145.	1.6	7

DAVID METZGER

#	Article	IF	CITATIONS
37	The Mid-Atlantic Center for AIDS Research Consortium Scholars Program: A Multi-Institutional Approach to Mentoring the Next Generation of Underrepresented Scientists. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, S124-S127.	0.9	7
38	Mental Health, Social Influences, and HIV Pre-exposure Prophylaxis (PrEP) Utilization Among Men and Transgender Individuals Screening for HIV Prevention Trials. AIDS and Behavior, 2021, 25, 524-531.	1.4	5
39	Prior Sexually Transmitted Infection and Human Immunodeficiency Virus Risk Perception in a Diverse At-Risk Population of Men Who Have Sex with Men and Transgender Individuals. AIDS Patient Care and STDs, 2021, 35, 15-22.	1.1	5
40	Clinic screening for adverse childhood experiences in people living with HIV to Improve Care Delivery. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2022, 34, 1094-1102.	0.6	2
41	HIV-1 and hepatitis C virus selection bottleneck in Chinese people who inject drugs. Aids, 2018, 32, 309-320.	1.0	0
42	1268. Clinic Screening for Adverse Childhood Experiences among Persons with HIV: A Pilot Project. Open Forum Infectious Diseases, 2019, 6, S456-S456.	0.4	0
43	No differences in delay discounting between smokers with and without HIV. Psychopharmacology, 2021, 238, 529-537.	1.5	Ο